You are here:

maraviroc (Celsentri)

Advice

Following a resubmission

maraviroc (Celsentri®) is not recommended for use within NHS Scotland in combination with other antiretroviral medicinal products, for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.

When added to optimised background therapy, maraviroc was associated with a significant reduction in viral load compared with addition of placebo in heavily pre-treated patients. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: maraviroc (Celsentri)
SMC Drug ID: 458/08
Manufacturer: Pfizer Ltd
Indication: For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 13 October 2008

Archived Advice

Full submission 7 April 2008

Back